Opinion

Video

Overcoming Unmet Needs in Treating mCSPC: ADT Monotherapy vs Multimodal Approaches

Key Takeaways

  • mCSPC treatment requires personalized approaches, considering disease burden, patient comorbidities, and genetic profiles to optimize outcomes.
  • There is a significant need for more effective therapeutic strategies to improve patient outcomes in mCSPC.
SHOW MORE

Panelists discuss how some of the most critical challenges and unmet needs in the treatment and management of metastatic castration-sensitive prostate cancer (mCSPC) include the effectiveness of monotherapy, the need for better risk stratification, and the integration of novel therapies to improve patient outcomes.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.